Estimating the Economically Justifiable Price of Limited-Duration Treatment with Donanemab for Early Symptomatic Alzheimer’s Disease in the United States

Estimating the Economically Justifiable Price of Limited-Duration Treatment with Donanemab for Early Symptomatic Alzheimer’s Disease in the United States

Abstract Introduction The goal of this economic model is to estimate an economically justifiable price (EJP) for using donanemab for the treatment of early symptomatic Alzheimer’s disease (AD) in the United States based on clinical data from the phase 3 TRAILBLAZER-ALZ 2 trial (NCT04437511). Methods...

Full description

Saved in:
Bibliographic Details
Main Authors: Malaz Boustani, Erin G. Doty, Louis P. Garrison Jr, Lee J. Smolen, Timothy M. Klein, Daniel R. Murphy, Andrew W. Spargo, Mark Belger, Joseph A. Johnston
Format: Article
Language:English
Published: Adis, Springer Healthcare 2024-09-01
Series:Neurology and Therapy
Subjects:
Donanemab
Alzheimer’s disease
Cost-effectiveness
Economically justifiable price
Amyloid-targeting therapies
Online Access:https://doi.org/10.1007/s40120-024-00649-y
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s40120-024-00649-y

Similar Items